Rein Therapeutics Inc Market Cap ($57.58 Million)
Market Cap & Net Worth: Rein Therapeutics Inc (RNTX)
Rein Therapeutics Inc market cap. Rein Therapeutics Inc (NASDAQ:RNTX) has a market capitalization of $57.58 Million ($57.58 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21147 globally and #4769 in its home market, demonstrating a 14.45% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rein Therapeutics Inc's stock price $0.67 by its total outstanding shares 86267032 (86.27 Million). Also see RNTX cash generation efficiency for how efficiently the company converts equity into cash flow.
Rein Therapeutics Inc Market Cap History (2025–2026)
Rein Therapeutics Inc market cap history from 2025 to 2026. Data shows change from $100.07 Million to $57.58 Million (-45.44% CAGR). Check current stock price of Rein Therapeutics Inc for real-time trading data and today's change.
Index Memberships
Rein Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #603 of 976 |
Weight: Rein Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rein Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rein Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore RNTX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RNTX by Market Capitalization
Companies near Rein Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see Rein Therapeutics Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Rein Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Rein Therapeutics Inc (2025–2026)
Market capitalization of Rein Therapeutics Inc from 2025 to today. Between 2025 and today, Rein Therapeutics Inc's market cap moved from $100.07 Million to $ 57.58 Million, with a yearly change of -45.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $57.58 Million | -42.46% |
| 2025 | $100.07 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Rein Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.58 Million USD |
| MoneyControl | $57.58 Million USD |
| MarketWatch | $57.58 Million USD |
| marketcap.company | $57.58 Million USD |
| Reuters | $57.58 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more